Page 90 - PRESENTATION

Immediate ADT Post-RP vs ADT on Detection of Metastases

or Symptomatic Recurrence

Immediate ADT N=47 Observation N=51

Overall survival Prostate-cancer-specific survival Progression-free survival

1.0 1.0 1.0
Immediate ADT
0.9 0.9 0.9
Immediate ADT Immediate ADT
0.8 0.8 0.8

0.7 0.7 Observation 0.7
Proportion alive 0.5 Observation Proportion alive without prostate cancer 0.5 Proportion alive and progression-free 0.5 Observation
0.6
0.6
0.6

0.4
0.4
0.4
0.3
0.3
0.3
0.2
HR, (95% CI)=4.09 (1.76-9.49)
HR, (95% CI)=3.42 (1.96-5.98)
HR, (95% CI)=1.84 (1.01-3.35)
0.1
0.1
0.1 Log-rank p=0.04 0.2 Log-rank p=0.0004 0.2 Log-rank p<0.0001
0.0 0.0 0.0
0 1 2 3 4 5 6 7 8 9 10 11 12 0 1 2 3 4 5 6 7 8 9 10 11 12 0 1 2 3 4 5 6 7 8 9 10 11 12
Time (years) Time (years) Time (years)
No. at risk

Immediate ADT 47 47 47 46 43 42 41 41 36 35 33 25 14 47 47 47 46 43 42 41 41 36 35 33 25 14 47 47 46 45 42 40 40 39 36 35 32 24 13

Observation 51 51 49 48 45 38 35 32 31 30 25 17 10 51 51 49 48 45 38 35 32 31 30 25 17 10 50 40 31 29 26 19 19 18 17 16 13 8 6

Early ADT benefits patients with nodal metastases who have undergone prostatectomy and

lymphadenectomy, compared with those who receive deferred treatment.

91 Messing EM et al. Lancet Oncol 2006: 7: 472–79